Rational design of a trispecific antibody targeting the HIV-1 Env with elevated anti-viral activity

被引:66
作者
Steinhardt, James J. [1 ,2 ]
Guenaga, Javier [3 ]
Turner, Hannah L. [4 ]
McKee, Krisha [5 ]
Louder, Mark K. [5 ]
O'Dell, Sijy [5 ]
Chiang, Chi-I [1 ]
Lei, Lin [1 ]
Galkin, Andrey [1 ,6 ]
Andrianov, Alexander K. [1 ]
Doria-Rose, Nicole A. [5 ]
Bailer, Robert T. [5 ]
Ward, Andrew B. [4 ]
Mascola, John R. [5 ]
Li, Yuxing [1 ,2 ,6 ]
机构
[1] Univ Maryland, Inst Biosci & Biotechnol Res, Rockville, MD 20850 USA
[2] Univ Maryland, Virol Program, College Pk, MD 20740 USA
[3] Scripps Res Inst, IAVI Neutralizing Antibody Ctr, La Jolla, CA 92037 USA
[4] Scripps Res Inst, Dept Integrat Struct & Computat Biol, La Jolla, CA 92037 USA
[5] NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA
[6] Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA
关键词
HUMAN MONOCLONAL-ANTIBODIES; BROADLY NEUTRALIZING ANTIBODIES; HUMAN-IMMUNODEFICIENCY-VIRUS; BISPECIFIC ANTIBODIES; IMPROVES PROTECTION; FITNESS COST; POTENCY; BREADTH; DIVERSITY; INFECTION;
D O I
10.1038/s41467-018-03335-4
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
HIV-1 broadly neutralizing antibodies (bNAbs) are being explored as passively administered therapeutic and preventative agents. However, the extensively diversified HIV-1 envelope glycoproteins (Env) rapidly acquire mutations to evade individual bNAbs in monotherapy regimens. The use of a "single" agent to simultaneously target distinct Env epitopes is desirable to overcome viral diversity. Here, we report the use of tandem single-chain variable fragment (ScFv) domains of two bNAbs, specific for the CD4-binding site and V3 glycan patch, to form anti-HIV-1 bispecific ScFvs (Bi-ScFvs). The optimal Bi-ScFv crosslinks adjacent protomers within one HIV-1 Env spike and has greater neutralization breadth than its parental bNAbs. Furthermore, the combination of this Bi-ScFv with a third bNAb recognizing the Env membrane proximal external region (MPER) results in a trispecific bNAb, which has nearly pan-isolate neutralization breadth and high potency. Thus, multispecific antibodies combining functional moieties of bNAbs could achieve outstanding neutralization capacity with augmented avidity.
引用
收藏
页数:12
相关论文
共 67 条
[1]   scFv Antibody: Principles and Clinical Application [J].
Ahmad, Zuhaida Asra ;
Yeap, Swee Keong ;
Ali, Abdul Manaf ;
Ho, Wan Yong ;
Alitheen, Noorjahan Banu Mohamed ;
Hamid, Muhajir .
CLINICAL & DEVELOPMENTAL IMMUNOLOGY, 2012,
[2]   Contour length and refolding rate of a small protein controlled by engineered disulfide bonds [J].
Ainavarapu, Rama Koti ;
Brujic, Jasna ;
Huang, Hector H. ;
Wiita, Arun P. ;
Lu, Hui ;
Li, Lewyn ;
Walther, Kirstin A. ;
Carrion-Vazquez, Mariano ;
Li, Hongbin ;
Fernandez, Julio M. .
BIOPHYSICAL JOURNAL, 2007, 92 (01) :225-233
[3]   Broadly neutralizing antibody and the HIV reservoir in acute HIV infection: a strategy toward HIV remission? [J].
Ananworanich, Jintanat ;
McSteen, Brian ;
Robb, Merlin L. .
CURRENT OPINION IN HIV AND AIDS, 2015, 10 (03) :198-206
[4]   Bispecific Antibodies Targeting Different Epitopes on the HIV-1 Envelope Exhibit Broad and Potent Neutralization [J].
Asokan, M. ;
Rudicell, R. S. ;
Louder, M. ;
McKee, K. ;
O'Dell, S. ;
Stewart-Jones, G. ;
Wang, K. ;
Xu, L. ;
Chen, X. ;
Choe, M. ;
Chuang, G. ;
Georgiev, I. S. ;
Joyce, M. G. ;
Kirys, T. ;
Ko, S. ;
Pegu, A. ;
Shi, W. ;
Todd, J. P. ;
Yang, Z. ;
Bailer, R. T. ;
Rao, S. ;
Kwong, P. D. ;
Nabel, G. J. ;
Mascola, J. R. .
JOURNAL OF VIROLOGY, 2015, 89 (24) :12501-12512
[5]   Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption [J].
Bar, K. J. ;
Sneller, M. C. ;
Harrison, L. J. ;
Justement, J. S. ;
Overton, E. T. ;
Petrone, M. E. ;
Salantes, D. B. ;
Seamon, C. A. ;
Scheinfeld, B. ;
Kwan, R. W. ;
Learn, G. H. ;
Proschan, M. A. ;
Kreider, E. F. ;
Blazkova, J. ;
Bardsley, M. ;
Refsland, E. W. ;
Messer, M. ;
Clarridge, K. E. ;
Tustin, N. B. ;
Madden, P. J. ;
Oden, K. S. ;
O'Dell, S. J. ;
Jarocki, B. ;
Shiakolas, A. R. ;
Tressler, R. L. ;
Doria-Rose, N. A. ;
Bailer, R. T. ;
Ledgerwood, J. E. ;
Capparelli, E. V. ;
Lynch, R. M. ;
Graham, B. S. ;
Moir, S. ;
Koup, R. A. ;
Mascola, J. R. ;
Hoxie, J. A. ;
Fauci, A. S. ;
Tebas, P. ;
Chun, T-W .
NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (21) :2037-2050
[6]   Immunologic strategies for HIV-1 remission and eradication [J].
Barouch, Dan H. ;
Deeks, Steven G. .
SCIENCE, 2014, 345 (6193) :169-174
[7]   Bispecific Anti-HIV-1 Antibodies with Enhanced Breadth and Potency [J].
Bournazos, Stylianos ;
Gazumyan, Anna ;
Seaman, Michael S. ;
Nussenzweig, Michel C. ;
Ravetch, Jeffrey V. .
CELL, 2016, 165 (07) :1609-1620
[8]   GENERATION OF HUMAN MONOCLONAL-ANTIBODIES AGAINST HIV-1 PROTEINS - ELECTROFUSION AND EPSTEIN-BARR-VIRUS TRANSFORMATION FOR PERIPHERAL-BLOOD LYMPHOCYTE IMMORTALIZATION [J].
BUCHACHER, A ;
PREDL, R ;
STRUTZENBERGER, K ;
STEINFELLNER, W ;
TRKOLA, A ;
PURTSCHER, M ;
GRUBER, G ;
TAUER, C ;
STEINDL, F ;
JUNGBAUER, A ;
KATINGER, H .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1994, 10 (04) :359-369
[9]   Antibody responses to envelope glycoproteins in HIV-1 infection [J].
Burton, Dennis R. ;
Mascola, John R. .
NATURE IMMUNOLOGY, 2015, 16 (06) :571-576
[10]   A LARGE ARRAY OF HUMAN MONOCLONAL-ANTIBODIES TO TYPE-1 HUMAN-IMMUNODEFICIENCY-VIRUS FROM COMBINATORIAL LIBRARIES OF ASYMPTOMATIC SEROPOSITIVE INDIVIDUALS [J].
BURTON, DR ;
BARBAS, CF ;
PERSSON, MAA ;
KOENIG, S ;
CHANOCK, RM ;
LERNER, RA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (22) :10134-10137